
News|Articles|July 1, 2009
FDA Pipeline preview, July 2009 (bucindolol, botulinum toxin type A, rivaroxaban, quetiapine, olanzapine, ziprasidone, ofatumumab, pegloticase, pralatrexate, melphalan, paclitaxel)
Recent FDA action (through July 2009) related to bucindolol, botulinum toxin type A, rivaroxaban, quetiapine, olanzapine, ziprasidone, ofatumumab, pegloticase, pralatrexate, melphalan, and paclitaxel
Advertisement
Complete response
Recommended for approval
Fast-track designations
Orphan drug designations
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Neffy’s first year: $72.2m in sales, 10,000 schools and broadening payer access
2
Centanafadine hits primary and key secondary endpoints in ADHD phase 3b trial
3
New study confirms benefits of GLP-1 drugs in patients with PAD
4
Brukinsa/rituximab cuts progression risk 43% in mantle cell lymphoma
5
































